JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Extra Ordinary General Meeting (EGM) On 17 June, 2022 At 1100 Hours.
Intimation for Notice of Extra Ordinary General Meeting to be held on 17 June, 2022 at 1100 hours through Video Conferencing or Other Audio-Visual Means, Book Closure and Record Date for remote E- voting. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company JAGSONPAL PHARMACEUTICALS LTD. 2 CIN NO. L74899DL1978PLC009181 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2021-22 2022-23 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-22 2022-23 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-NANDITA SINGHDesignation :-COMPANY SECRETARY Name of the Chief Financial Officer :- SV SUBHA RAO Designation : -CFO Date: 16/05/2022 JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Outcome for Outcome Of The Board Meeting
Outcome of the Board Meeting. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Board Meeting Intimation for Intimation For The '1St/2022-23' Board Meeting.
JAGSONPAL PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/05/2022 ,inter alia, to consider and approve the alteration in AOA and other routine matters. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayJAGSONPAL PHARMACEUTICALS LTD. 2CINL74899DL1978PLC009181 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: NANDITA SINGH Designation: COMPLIANCE OFFICER EmailId: nandita.singh@jagsonpal.com Name of the Chief Financial Officer: SALAPAKA VENKATA SUBHA RAO Designation: CFO EmailId: svrao@jagsonpal.com Date: 30/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Submission Of Certificate Under Sub- Regulation 9 & 10 Regulation 40 Of The SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 For The Year Ended 31St March, 2022.
Submission of Certificate under Sub- Regulation 9 & 10 Regulation 40 of the SEBI (Listing Obligations & Disclosure Requirement) Regulations, 2015 for the year ended 31st March, 2022. JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jasbir Kaur Kochhar JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajpal Singh Kochhar JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajpal Singh Kochhar JAGSONPAL PHARMACEUTICALS LTD. - 507789 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rajpal Singh Kochhar